Geron set to nab Europe orphan drug tag for imetelstat for bone marrow disorder

The European Medicines Agency’s Committee for Orphan Medicinal Products has issued a positive opinion backing Orphan Drug status for Geron’s (NASDAQ:GERN) imetelstat for the treatment of myelodysplastic syndromes, a rare group of bone marrow failure disorders.

Among the benefits of Orphan Drug status in Europe is a 10-year period of market exclusivity for the indication, if approved.

https://seekingalpha.com/news/3587696-geron-poised-to-nab-orphan-drug-tag-in-europe-for-imetelstat-for-bone-marrow-disorder